Mereo Biopharma Group (MREO) investor relations material

Executive summary

• Entered an Option and License Agreement with Sentynl for alvelestat, targeting AATD-LD, with potential $40M upfront/R&D, $435M milestones, and double-digit royalties.

• Focused on rare disease therapeutics, with late-stage candidates setrusumab (OI) and alvelestat (AATD-LD), and early-stage vantictumab (ADO2); vantictumab advancing toward Phase 2 with partner āshibio.

• Engaged with regulatory agencies for setrusumab in OI; Phase 3 studies did not meet primary endpoints but showed meaningful effects; updates expected by year-end 2026.

• Cash and cash equivalents were $30.1M as of June 30, 2026, expected to fund operations into late 2027.

Financial highlights

• No revenue recognized in Q2 or H1 2026; prior year included a $0.5M milestone payment.

• Net loss for Q2 2026 was $7.0M, improved from $14.6M in Q2 2025; H1 2026 net loss was $13.7M, improved from $27.5M in H1 2025.

• R&D expenses decreased to $1.8M in Q2 2026 (from $5.4M), mainly due to reduced setrusumab and alvelestat spending.

• General and administrative expenses fell to $5.2M in Q2 2026 (from $5.5M), reflecting cost savings and delayed pre-commercial investments.

• Cash and cash equivalents declined to $30.1M from $41.0M at year-end 2025.

Outlook and guidance

• Cash runway expected to fund operations into late 2027, excluding potential Sentynl payments; additional funding will be needed for full development and commercialization.

• Plans to seek non-dilutive funding, equity, or debt to support ongoing and future programs.

• Phase 3 trial for alvelestat could begin in early 2027, contingent on Sentynl exercising its option.

• Ongoing regulatory discussions for setrusumab and preparation for alvelestat Phase 3 trial.